Correlation between iron regulatory protein-1 (G-32373708A) and -2 (G-49520870A), gene variations and migraine susceptibility in southeast Iran: A case-control study

Nourollah Ramroodi, Mehdi Jahantigh, Tooba Nakhzari-Khodakheir, Nasrin Ranjbar, Nima Sanadgol

Department of Neurology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
Department of Pathology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
Qianceh Biotechnology Company, Sistan & Baluchestan, Zahedan, Iran
Department of Biochemistry, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
Department of Biology, Faculty of Sciences, University of Zabol, Zabol, Iran
Young Researchers and Elite Club, Zahedan Branch, Islamic Azad University, Zahedan, Iran

Abstract

Migraine is a chronic neurological disease characterized by recurrent moderate to severe headaches commonly in association with neuro-inflammation. Iron regulatory proteins (IRPs) regulate the expression of iron metabolism genes and control cytosolic iron concentrations in order to optimize cellular iron availability. The current study aimed to investigate the possible associations IRP-1 and -2 single nucleotide polymorphisms (SNPs) and susceptibility to migraine in Iranian patients. In a prospective case-control study, we studied blood samples of 190 patients with migraine and 200 healthy controls for analysis of gene variants. Genotyping for the IRP-1 SNP: G-32373708A (rs867469), and IRP-2 SNP: G-49520870A (rs17483548) were performed using PCR-ASO and PCR-RFLP respectively. Statistical analysis was performed using the SPSS version 21.0 (SPSS, Chicago) and SNPStats version 1.14.0. Among IRP SNPs, rs867469 (GG genotype, adjusted OR = 3.82, 95% CI = 1.131–12.953, P = 0.031) and rs17483548 (GG genotype, adjusted OR = 19.12, 95% CI = 3.69–99.05, P = 0.001) were significantly associated with migraine. The most frequent genotypes in the migraineurs were GA in both SNPs rs867469 (58%), and rs17483548 (68%). Moreover, there was significant statistically relationship between rs17483548 SNP (GG genotype, adjusted OR = 0.10, 95% CI = 0.013–0.745, P = 0.025) and different subclasses (without and with aura) of migraine. Our data indicated that G/G genotypes in both the G-32373708A-IRP-1 and G-49520870A-IRP-2 polymorphisms could be associated with increased risk for migraine. Therefore, it is suggested that in addition to other factors, IRP-1 and IRP-2SNPs may play a pivotal role in the migraine.

1. Introduction

Migraine is a rigorous and painful headache accompanied with sensory warning and is a public health problem of great impact on both the patient and society [1]. The two major subclasses of migraine are common migraine (without aura) and classic migraine (with aura or neurological symptoms) [2]. Since about half of migraineurs (migraine patients) do not pursue medical attention and there is no economic, social or ethnic limitation, it is difficult to precisely determine of disease prevalence in the community [3]. It seems that about 15 to 16 percent of women and 5 to 9 percent of men are affected with migraine and its prevalence is highest among the ages of 30–49 worldwide [4]. Migraine etiology is multifactorial, involving both various genetic and environmental factors, but scientists consider three important mechanisms for its pathophysiology including: inflammatory, neurological and cardiovascular impairments [5,6]. Cell and molecular association studies may point to the novel molecules that mediate migraine disorder and enable its management. According to the theory of neuro-inflammation, in the migraine, ion channels (Na²⁺, Ca²⁺, K⁺) and inflammatory mediators activation in the meninges sensory nerves, stimulates pain receptors in these area [7,8].
has been shown that headaches are a common symptom of iron deficiency and prolonged headaches may even become chronic. On the other hand iron deficiency anemia and migraine attacks have been reported but there are conflicting results on the mechanisms involved [9–14]. The accumulation of iron ions is related to the frequency of migraine attacks, being greatest in chronic migraine where the attacks may occur daily [15]. It is known that diminution of iron migraine attacks, being greatest in chronic migraine where the accumulation of iron ions is related to the frequency of iron deficiency anemia and migraine attacks have been reported in pain threshold modulation [16]. Iron regulatory proteins (IRPs), also known as iron-responsive element-binding proteins (IRE-BP) regulate iron metabolism via binding to iron responsive elements in mRNA. IRP-1 or aconitase-1 (ACO-1) has aconitase activity, and catalyze conversion of citrate to isocitrate and they are iron-sulfur proteins that they require a 4Fe-4S cluster for their enzymatic activity [17]. IRP-2 is more expressed in intestine and brain, less abundant than IRP-1 in other regions and has no ACO activity [18–20]. The human IRP-1 gene is located on chromosome 9p21.1 and IRP-2 gene is located on chromosome 15q25.1. So far, several allelic variants polymorphisms have been found in IRPs gene [http://www.ncbi.nlm.nih.gov/snp], and g.32373708 G > A-IRP1 (rs867469) single nucleotide polymorphisms (SNPs) were analyzed through allele-specific oligonucleotide-PCR method (ASO-PCR) method [24,25]. PCR amplifications were performed in a final volume of 20 μl containing, 10 μl master mix (TAKARA, Tokyo, Japan), 0.7 μl (10 pmol) of each primer, 2 μl template DNA, and 6.6 μl DNase-free water was used. The amplification was performed in Bio-Rad Thermal Cycler with an initial denaturation step at 95 °C for 5 min; followed by 35 cycles at 95 °C for 30 s, 56 °C for 35 s, and 72 °C for 30 s with a final extension at 72 °C for 5 min. The primers designed to detect the rs867469 SNP were as follows: allele specific sense oligonucleotides 5'-TGCAACCTCAGAAAG-3' for G variant and 5'-TGCAACCTCAGAAAG-3' for A variant and antisense oligonucleotide 5'-CTAGATTGAACTTGGAGG-3'. The PCR product (237 bp) was checked for size and purity by 8% polyacrylamide gel electrophoresis, stained with ethidium bromide and viewed under UV light.

2. Materials and methods

2.1. Patients and samples

The study was approved ethically in medical research committee at Zahedan University of Medical Sciences, and was conducted with clinical samples from migraine patients (N = 190, age: 13 to 66 years) who were treated at the Department of Neurology, Alibah Abitaleb Hospital, Zahedan, Iran, from August 2013 to February 2014. Healthy controls (HCs) without any inflammatory, neurological diseases, migraine headache and specific systemic disease (N = 200, age: 15–75 years) from volunteer blood donors were selected during same time. A diagnosis of migraine was made according to standardized criteria of international headache classification [21]. Patients were excluded if they had anemia related diseases or received iron supplement. Patients adjusted in two definite groups without aura (N = 112, 76 female and 36 male) and with aura (N = 78, 56 female and 22 male) subtypes of migraine. All patients were informed of the study and participated voluntarily and written consents were taken. The work is carried out in accordance with the code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments in humans.

2.2. Blood collection and DNA extraction

Whole blood (10 mL) samples were taken from all subjects and collected in separator tubes (contain EDTA, 0.5 M) and centrifuged for 15 min at 150g (gravity) at 20 °C and then serum was stored at −20 °C in sterile plastic tubes for DNA extraction. Genomic DNA was extracted from the serum of 190 subjects with migraine headaches and 200 HCs using the DNA extraction kit (DIAtom DNA Prep., GORDIZ, Moscow, Russia) according to the manufacturer’s instructions. DNA quality extracts were analyzed by electrophoresis. By NanoDrop DNA concentrations about 60 ng/μl was obtained and ratio of 260/280 nm around 1.7 to 1.9 was accepted [22].

2.3. IRP-1 Genotyping

Selection of SNPs was made on the basis of their location in the 5’ regulatory region, which commonly contains the promoter [23]. The g.32373708 G > A-IRP1 (rs867469) single nucleotide polymorphisms (SNPs) were analyzed through allele-specific oligonucleotide-PCR method (ASO-PCR) method [24,25]. PCR amplifications were performed in a final volume of 20 μl containing, 10 μl master mix (TAKARA, Tokyo, Japan), 0.7 μl (10 pmol) of each primer, 2 μl template DNA, and 6.6 μl DNase-free water was used. The amplification was performed in Bio-Rad Thermal Cycler with an initial denaturation step at 95 °C for 5 min; followed by 35 cycles at 95 °C for 30 s, 56 °C for 35 s, and 72 °C for 30 s with a final extension at 72 °C for 5 min. The primers designed to detect the rs867469 SNP were as follows: allele specific sense oligonucleotides 5'-TGCAACCTCAGAAAG-3' for G variant and 5'-TGCAACCTCAGAAAG-3' for A variant and antisense oligonucleotide 5'-CTAGATTGAACTTGGAGG-3'. The PCR product (237 bp) was checked for size and purity by 8% polyacrylamide gel electrophoresis, stained with ethidium bromide and viewed under UV light.

2.4. IRP-2 Genotyping

Selection of SNPs was made on the basis of their location in the 5’ regulatory region, which commonly contains the promoter [23]. The g.49520870G > A-IRP-2 (rs17483548) single nucleotide polymorphisms (SNPs) were analyzed through restriction fragment length polymorphism-PCR method (RFLP-PCR) method [24,25]. PCR amplifications were performed in a final volume of 20 μl containing, 10 μl master mix (TAKARA, Tokyo, Japan), 0.7 μl (10 pmol) of each primer, 2 μl template DNA, and 6.6 μl DNase-free water was used. The amplification was performed with an initial denaturation step at 95 °C for 5 min; followed by 35 cycles at 95 °C for 30 s, 60 °C for 35 s, and 72 °C for 30 s with a final extension at 72 °C for 5 min, using the following primers: sense 5’-CCCCCATT GAAAACG-3’ and antisense 5’-AGATCTCGACGGAGGAAAAC-3’.

The PCR product (360 bp) was checked for size and purity by 1.5% agarose gel electrophoresis. Final volume of 20 μl including 2 μl of 10 × Buffer, 0.5 μl of enzyme, 7 μl of PCR product, 10.5 μl of double distilled water was used for all amplification products overnight at 37 °C, and 10 μl sample loaded for electrophoresis. Affil (Thermo Scientific) endonuclease digested pattern for rs2243250 amplification product were 183 bp and 177 bp for the GG, 183 bp, 177 bp and 360 bp for the GA and AA genotypes.

2.5. Statistical analysis

SPSS version 21.0 (SPSS, Chicago) and SNPStats version 1.14.0 were used for all the statistical analyses. The association between case-control status and each polymorphism, measured by the odds ratio (OR) and its corresponding 95% confidence interval (CI), was estimated using an unconditional multiple logistic regression model, both with and without adjustment for sex and age. The Hardy–Weinberg equilibrium (HWE) was tested with the X2 test for any of the SNPs under consideration. Smoking habit was categorized in terms of never smokers and smokers (including current and former). Stratified analysis according to age, sex, race, and migration was also conducted. To study a possible gene-environment interaction, the patients and controls were divided into subgroups depending on sex, race, age, migration, and...
smoking. Unconditional logistic regression analyzes were also performed to assess the association between genotypes and risk for migraine after stratification of the individuals according to sex, race, age, migration, and smoking. The significance level was set at $P \leq 0.05$ for all the tests.

3. Results

3.1. Demographic analysis and the risk of migraine independent of genotype

The characteristics of the patients with migraine and migraine free controls involved in this study are presented in Table 1. The mean ± SD age was 31.7 ± 10.17 years for the patients (range 13–66) and 35.1 ± 12.2 years for the controls (range 15–75) as well as 22% of the patients and 34% of the controls were men, whereas 78% of the patients and 66% of the controls were women. Moreover, we explored the relationships between gender, age, smoking, race and migration and the risk of migraine independently of genotype (Table 2). Our results suggested that there were no significant different between gender, age, smoking, race and migration among the controls and patients (Table 2). Therefore, age and gender variables (with lower $P$-value) were further adjusted in the multivariate logistic regression model to control for possible confounding factors of the main effects of the polymorphisms.

3.2. Association of IRP-1 SNP (rs867469 G/A) and migraine

The G/G, G/A and A/A genotypes of IRP-1 were found in 9%, 81% and 10% in HCs, in comparison with 31.5%, 58% and 10.5% in migraineurs, respectively. The allele frequency of IRP-1 rs867469 (G/A) were 49.5% (G), 50.5% (A) in HCs and 60.5% (G), 39.5% (A) in migraineurs, respectively (Table 3). Regarding the genotypes frequencies for the IRP-1 rs867469 (G/A), both case and control group are not consistent with HWE. Distributions of IRP-1 allele frequency in rs867469 (G) were significantly different between patients and controls (crude OR $= 1.56$, $P = 0.029$). Moreover distributions of IRP-1 GG polymorphism were significantly different between patients and controls (crude OR $= 3.33$, $P = 0.040$). On the other hand, the GG genotype increased the risk of migraine (adjusted OR $= 3.82$, $P = 0.031$). In conclusion, in the migraine patients, the G allele of the rs867469 G/A-IRP1 SNP increased the risk of the disease (adjusted OR $= 1.61$, $P = 0.023$) and the A allele decreased such risk (Table 3). AA and AG genotypes could be

| Table 1 |
| --- |
| Demographic distribution of migraine patients and control subjects enrolled in the study. |
| Characteristics | Control (n = 200) | Case (n = 190) |
| --- | N (%) | N (%) |
| Gender (male/female) | 68(34)/132(66) | 42(22)/148(78) |
| Age (year) | 174(87) | 180(95) |
| Age (year) | 26(13) | 10(5) |
| Mean ± SD | 35.1 ± 12.2 | 31.7 ± 10.17 |
| Range | 15–75 | 13–66 |
| Smoking (yes/no) | 80(40)/120(60) | 88(46)/102(54) |
| Race (parse/other) | 144(72)/56(28) | 146(77)/44(23) |
| Migrate (yes/no) | 96(48)/104(52) | 72(38)/118(62) |

| Table 2 |
| --- |
| Risk of migraine in association with gender, age, smoking, race and migration. |
| Characteristics | Control (n = 200) | Case (n = 190) | OR (95%CI) | $P$-value |
| --- | N (freq.) | N (freq.) | --- | --- |
| Gender | | | | |
| Males | 68(0.34) | 42(0.22) | 0.55(0.291–1.042) | 0.067 |
| Females | 132(0.66) | 148(0.78) | 1.81(0.960–3.433) | 0.067 |
| Age (year) | | | | |
| Age < 50 | 174(0.87) | 180(0.95) | 2.69(0.92–7.862) | 0.071 |
| Age ≥ 50 | 26(0.13) | 10(0.05) | 0.37 (0.127–1.108) | 0.071 |
| Smoking | | | | |
| Ever (current, former) | 80(0.40) | 88(0.46) | 1.29(0.73–2.28) | 0.37 |
| Never | 120(0.60) | 102(0.54) | 0.77(0.438–1.364) | 0.37 |
| Race | | | | |
| Persian | 142(0.71) | 146(0.77) | 1.35(0.712–2.579) | 0.35 |
| Other | 58(0.29) | 44(0.23) | 0.73(0.388–1.404) | 0.35 |
| Migrate | | | | |
| Yes | 96(0.48) | 72(0.38) | 0.66(0.374–1.170) | 0.15 |
| No | 104(0.52) | 118(0.62) | 1.51(0.855–2.677) | 0.15 |

Comparisons were performed by independent samples t-test $\chi^2$ of test results for categorical data, freq. = frequency, OR = odds ratio, CI = confidence interval, N = number.

| Table 3 |
| --- |
| Distribution of genotypes and frequency of alleles of the g.3273708 G/A-IRP-1 polymorphisms in patients with migraine and individuals without disease (controls). |
| IRP-1 (rs867469) | Control (n = 200) | Case (n = 190) | Crude OR (95%CI) | Crude P-value | Adjusted. OR* (95% CI) | Adjusted P-value* |
| --- | --- | --- | --- | --- | --- | --- |
| AA, No (%) | 20(10) | 20(10.5) | 1 | – | 1 | – |
| AG, No (%) | 162(81) | 110(58) | 0.67(0.265–1.740) | 0.421 | 0.63(0.242–1.642) | 0.345 |
| GG, No (%) | 18(9) | 60(31.5) | 3.33(1.055–10.530) | **0.040** | 3.82(1.131–12.953) | **0.031** |
| $P^* = 0.001$ | | | | | | |
| A allele | 101(50.5) | 75(39.5) | 1 | – | 1 | – |
| G allele | 99(49.5) | 115(60.5) | 1.56(1.047–2.338) | **0.029** | 1.61(1.068–2.428) | **0.023** |

CI: confidence interval, OR: odds ratio.
Significant $P$-values are in bold.
* Adjusted for age and sex.

The G/G, G/A and A/A genotypes of IRP-1 were found in 9%, 81% and 10% in HCs, in comparison with 31.5%, 58% and 10.5% in migraineurs, respectively. The allele frequency of IRP-1 rs867469 (G/A) were 49.5% (G), 50.5% (A) in HCs and 60.5% (G), 39.5% (A) in migraineurs, respectively (Table 3). Regarding the genotypes frequencies for the IRP-1 rs867469 (G/A), both case and control group are not consistent with HWE. Distributions of IRP-1 allele frequency in rs867469 (G) were significantly different between patients and controls (crude OR $= 1.56$, $P = 0.029$). Moreover distributions of IRP-1 GG polymorphism were significantly different between patients and controls (crude OR $= 3.33$, $P = 0.040$). On the other hand, the GG genotype increased the risk of migraine (adjusted OR $= 3.82$, $P = 0.031$). In conclusion, in the migraine patients, the G allele of the rs867469 G/A-IRP1 SNP increased the risk of the disease (adjusted OR $= 1.61$, $P = 0.023$) and the A allele decreased such risk (Table 3). AA and AG genotypes could be
considered as protective and GG genotype could be considered as risk factor in migraine headaches. Otherwise, there were no significant association with migraine subtypes and IRP-1 rs2070874 (G/A) SNP in this population (Table 5).

3.3. Association of IRP-2 SNP (rs17483548 G/A) and migraine

The G/G, G/A and A/A genotypes of IRP-2 were found in 15%, 77% and 8% in HCs, in comparison with 25.3%, 68.4% and 6.3% in migraineurs, respectively. The allele frequency of IRP-2 rs17483548 (G/A) were 54% (G), 64% (A) in HCs and 62.6% (G), 77% and 8% in migraineurs, respectively. The allele frequency of IRP-2 rs17483548 (G/A) were 54% (G), 64% (A) in HCs and 62.6% (G), 77% and 8% in migraineurs, respectively. The allele frequency of IRP-2 rs17483548 (G/A) SNP in this population (Table 4). Regarding the genotypes frequencies for the IRP-2 rs17483548 (G/A), both case and control group are not consistent with HWE. Distributions of IRP-2 allele frequency in rs17483548 were not significantly different between patients and controls (Table 4). Distributions of IRP-2 AG polymorphism were not different between patients and controls before and after adjustment for age and sex (crude OR = 2.11, 95% CI = 0.77–5.752, P = 0.144). Distributions of IRP-2 GG polymorphism were not different between patients and controls (Table 4).

Table 4

| IRP-2 (rs17483548) | Control (n = 200) | Case (n = 190) | Crude OR (95%CI) | Crude ORa (95% CI) | Adjusted OR (95% CI) | Adjusted ORa (95% CI) |
|-------------------|------------------|---------------|----------------|-------------------|---------------------|---------------------|
| AA, No (%)        | 16(8.0)          | 12(6.3)       | 1              | 1                 | 1                   | 1                   |
| AG, No (%)        | 154(77.0)        | 130(68.4)     | 2.11(0.77–5.752) | 0.144             | 0.63(0.242–1.642)   | 0.133               |
| GG, No (%)        | 30(15.0)         | 48(25.3)      | 7.5(2.171–25.906) | 0.001             | 19.12(3.69–99.05)   | 0.001               |

P* = 0.002

A allele | 92(46.0) | 71(37.4) |
G allele | 108(54.0) | 119(62.6) | 1.42(0.953–2.140) | 0.085 | 1.51(0.998–2.288) | 0.051 |
P = 0.08

Table 5

| IRP-1 (rs867469) | With aura, No (%) (n = 78) | Without aura, No (%) (n = 112) | OR(95%CI) | P-value |
|------------------|----------------------------|--------------------------------|-----------|---------|
| AA, No (%)       | 8(10.3)                    | 12(10.7)                       | 1         | 0.033   |
| AG, No (%)       | 34(43.6)                   | 76(67.9)                       | 1.49(0.372–5.973) | 0.573   |
| GG, No (%)       | 36(46.2)                   | 24(21.4)                       | 0.49(1.013–1.915) | 0.277   |

P = 0.007

IRP-2 (rs17483548) | 126

A allele | 8(7.1) |
G allele | 96(85.7) | 34(34.6) | 1.41(0.237–8.416) | 0.705 |
P = 0.001

AA, No %| 8(7.1) |
AG, No %| 96(85.7) |
GG, No %| 34(34.6) |
P = 0.001

4. Discussion

Migraine is a severe neurological disorder that causes a strong throbbing or pulsating pain in one area of the head and can be accompanied by nausea, vomiting and extreme photophobia [2]. Several studies used a candidate gene approach to elucidate genetic contribution to neuropathic pain phenotypes; however, the data is limited and inconsistent [26,27]. The genetic background of migraine consists of common or overlapped pathways and the responsible genes may provide insight regarding the pathophysiological mechanisms that can explain their comorbidity with migraine [28,29]. Data from the large cohort of Caucasian women (n = 25,713) in 77 different SNPs suggested that there is an association between variants in some inflammatory mediators including TNF-α rs673 (OR = 0.52, 95% CI = 0.30–0.89, P = 0.017), CCR2 rs1799864 (OR = 1.12, 95% CI = 1.03–1.21, P = 0.007), TGFβ1 rs1800469 (OR = 0.93, 95% CI = 0.89–0.89, P = 0.009), NOS3 rs3918226 (OR = 1.13, 95% CI = 1.01–1.27, P = 0.04), and IL-9 rs2069885 (OR = 1.12, 95% CI = 1.02–1.24, P = 0.02) with migraine [30]. Although the pathogenesis of migraine is not completely detected, a growing viewpoint of assays offers that oxidative stress and free radical damage may worsen or aggravate migraine susceptibility [31,32]. In a clinical study, migraine patients that take antioxidant supplements had shown a progressive effects in migraine therapy, offering that oxidative stress is someway contributed in its pathogenesis [33]. Iron is assumed as a possible origin of oxidative radicals related to destructive activities affecting the CNS [34]. Although iron can cause oxidative tissue injury through the Haber–Weiss and Fenton response, it is also a necessary for many metabolic pathways. Several studies have detected that iron imbalance load may have a vital role in the pathogenesis of migraine [12,35]. In mammals, two homologous IRPs have been recognized, IRP-1 and IRP-2. IRP-1, is a multi-functional protein that acts as an iron-responsive element (IRE)-binding protein contributing in the control of iron metabolism by linkage of mRNA to suppress translation [36]. It acts also as the cytoplasmic isoform of aconitase. Aconitases are iron-sulfur proteins and requirement 4Fe-4S cluster for their enzymatic function, in which they catalyze transform of citrate to isocitrate [37]. IRP-2 also called IREB-2 (iron-responsive element binding protein 2) have 79% similarity to IRP-1 but not have aconitase activity [38]. Under the circumstances of iron-deficiency, IRPs bind to IREs exist in the 5' UTR of mRNAs, such as in ferritin heavy and light chains and suppress...
translation and at the same time IRPs bind to mRNAs including IREs in the 3’ UTR, such as TR-1 and DMT-1, that lead to increase RNA stability. And conversely, under iron overload circumstance, IRPs bind to IREs is decreased. So, under iron-deficiency circumstances, IRPs up-regulate genes related to enhance iron uptake and under iron overload circumstances, IREs up-regulates genes related to storage of iron level [39]. The significance of balance iron homeostasis is emphasized by the reality that neurological disorders has been seen in some pathological circumstance due to overload of iron. Targeted deletions of IRP-1 and IRP-2 in animals have demonstrated that they are the chief physiologic iron sensors [40]. Some data confirmed that multiple genes are contributed with extension of migraine in different populations [41,42]. In related with other neurological disorders, Deplazes et al., indicated that mutations (non-synonymous polymorphism, I888V) in exon 21 and a –88C>T polymorphism in the promoter region) in the IRP-2 gene were not a common cause of Parkinson’s disease associated with substantia nigra iron accumulation [43]. In this study, for the first time we focused on IRPs in patients with migraine headaches to examine the hypothesis that say migraine headaches could related to iron unbalance. Therefore, our results for the first time provided evidence that enhance our understanding of how migraine may relate to these IRPs gene variation. We evaluated whether the g.32373708 G > A polymorphism in the IRP-1 gene and the g.49520870 G > A polymorphism in the IRP-2 gene affect on the risk of migraine. As far as we know, the g.32373708 G > A-IRP1 polymorphism and the g.49520870 G > A-IRP2 polymorphism have not been studied in migraine patients so far. We observed that the incidence of migraine was positively associated with the attendance of the G/C genotype of the IRP1 and IRP-2 SNPs. Our study demonstrated that none of age, sex, race, and smoking factors have not association with migraine. In this study the genotypes frequencies in both case and control groups are not consistent with HWE, so we regarded this issue as an important limitation of our study. At the moment we have logical reason of this data, bating that environmental factors may have effect in migraine pathogenesis at least in this population. However, to achieve better results and determine the role of different environmental factors in migraine susceptibility should be done experiments in the broader population. Similar studies enrolling greater sample sizes and composed of other ethnic groups from different countries may contribute to confirming our findings and therefore these results should be taken as preliminary. In conclusion, our work shows that genetic polymorphisms of the IRPs genes may be associated with development of migraine. These findings may be useful in augment of the cause of migraine.

Conflict of interest

All the authors declare that they do not have financial disclosure or conflicts of interest.

Acknowledgements

We are indebted to the healthcare personnel of Department of Neurology, Ali-ebn Abitaleb Hospital for providing patient support and the samples analyzed in this study. This study was funded by the Zahedan University of Medical Sciences, Zahedan, Iran.

References

[1] Goadsby PJ. Recent advances in the diagnosis and management of migraine. BMJ 2008;337(7652):25–9.
[2] Lipton RB, Bigal ME, Steiner J, et al. Classification of primary headaches. Neurology 2004;63(3):427–35.
[3] Victor TW, Hu X, Campbell JC, et al. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 2010;30(9):1065–72.
[4] Stovner LJ, Hagen K. Prevalence burden and cost of headache disorders. Curr Opin Neurol 2006;19(3):281–5.
[5] Mulder EJ, Van Baal C, Gaist D, et al. Genetic and environmental influences on migraine: a twin study across six countries. Twin Research 2003;6(6):422–31.
[6] Pietrobon D, Moskowitz MA. Pathophysiology of Migraine. Annu Rev Phys 2013;75:365–91.
[7] Strober C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology 2005;64(10 Suppl 2):59–15.
[8] Yan J, Dussor G. Ion channels and migraine. Headache 2014;54(4):519–39.
[9] Vuković-Cvetković V, Plavec D, Lovrencic-Huzjan A, et al. Is iron deficiency anemia related to migraines? Pain Headache Rep 2013;1:107–13.
[10] Ramroodi N, Niazi AA, Sanadgol N, Ganjali Z, Sarabandi V. Evaluation of serum iron level in migraine. Iran J Ped Hematol Oncol 2016;6(1):32–7.
[11] Gür-Özmen S, Karahan-Ozcan R. Iron deficiency anemia is associated with menstrual migraine: a case-control study. Pain Med 2015; pii: pmv029.
[12] Comuñí H, Comunlí E, Caradas S, et al. The levels of trace elements and heavy metals in patients with acute migraine headache. J Pak Med Assoc 2015;65(7):694–7.
[13] Pumuk GE, Top MS, Uyanik MS, et al. Is iron-deficiency anemia associated with migraine? Is there a role for anxiety and depression? Wien Klin Wochenschr 2016;128(8):576–80.
[14] Gupta R, Lahan V, Goel D. Serum iron may not be linked with migraine. Ann Indian Acad Neurol 2013;16(3):462.
[15] Wolch RMA, Iron in the migraine brain: a resilient hypothesis. Cephalalgia 2009;29:283–5.
[16] Prashanth L, Kattapagari KK, Chitturi RT, et al. A review on role of essential trace elements in health and disease. J NTR Univ Health Sci 2012;1(4):75–85.
[17] Eisenstein RS. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr 2000;20:627–62.
[18] Hentze MW, Kühn LC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA 1996;93(16):8175–82.
[19] Henderson BR, Seiser C, Kühn LC. Characterization of a second RNA-binding protein in rodents with specificity for iron-responsive elements. J Biol Chem 1993;268(36):27327–34.
[20] Samaniego F, Chin J, Iwai K, et al. Molecular characterization of a second iron-responsive element-binding protein, iron regulatory protein 2. Structure, function, and post-translational regulation. J Biol Chem 1994;269(49):30904–10.
[21] Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. 2nd ed. Cephalalgia, 2004; Suppl 1 p. 1–160.
[22] Ramroodi N, Niazi AA, Sanadgol N, Ganjali Z, Sarabandi V. Evaluation of reactive Epstein-Barr Virus (EBV) in Iranian patient with different subtypes of multiple sclerosis (MS). Braz J Infect Dis 2013;17(2):156–63.
[23] Suwelack E, Pogorzelski M, Blasik J, et al. Genetic polymorphism of the iron-regulatory protein-1 and -2 genes in age-related macular degeneration. Mol Biol Rep 2012;39(6):7077–87.
[24] Khani M, Amani D, Taberiparank R, Sanadgol N, Feizollahzadeh S, Rahmani Z. Thyroid hormone growth factor beta-1 (TGF-β1) gene polymorphism and MTHFR polymorphism in migraine. Iran J Ped Hematol Oncol 2016;6(8):576–80.
[25] Schürks M, Kurth K, Buring JE, Zee1 RYL. A Candidate Gene Association Study on Iron Polymorphisms in Migraine. Eur J Hum Genet 2004;12(7):694–7.
[26] Boækowski L, Sobaniec W, Elazowska-Rutkowska B. Proinflammatory plasma cytokines in children with migraine. Pediatr Neurol 2009;41:17
[27] Henderson BR, Seiser C, Kühn LC. Characterization of a second RNA-binding protein in rodents with specificity for iron-responsive elements. J Biol Chem 1993;268(36):27327–34.
[28] Schürks M, Kurth K, Buring JE, Zee1 RYL. A Candidate Gene Association Study on 77 polymorphisms in migraine. J Pain 2009;10(7):759–66.
[29] Belfer I, Dai F. Phenotyping and genotyping neuropathic pain. Curr Pain Headache Rep 2010;14(3):203–12.
[30] Sathe S, Disorders Neurogenetic. Migraine and Neurogenetic Disorders. Curr Pain Headache Rep 2013;17(9):360.
[31] Kors E, Haan J, Ferrari M. Migraine genetics. Curr Pain Headache Rep 2003;7(3):212–7.
[32] Bozackowski L, Sobaniec W, Elazowska-Rutkowska B. Proinflammatory plasma cytokines in children with migraine. Pediatr Neurol 2009;41:17.
[33] Tuncel D, Tolutin Fi, Giske M, et al. Oxidative stress in migraine with and without aura. Biol Trace Elem Res 2008;126:92.
[34] Eren Y, Dirik E, Neselioglu S, Erol E. Oxidative stress and decreased thiol level in patients with migraine: cross-sectional study. Acta Neurol Belg 2015;115:643–9.
[35] Chayasirisobhon S. Use of a pine bark extract and antioxidant vitamin combination product as therapy for migraine in patients refractory to pharmacologic medication. Headache 2006;46(5):788–93.
[36] Andersen HH, Johnsen KB, Moos T. Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration. Cell Mol Life Sci 2014;71(9):1607–22.
[37] Krust MC, van Buchem MA, Launer LJ, et al. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia 2010;30(2):129–36.
[36] Muckenthaler MU, Galy B, Hentze MW. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr 2008;28:197–213.

[37] Bleackley MR, Wong AY, Hudson DM, et al. Blood iron homeostasis: newly discovered proteins and iron imbalance. Transfus Med Rev 2009;23(2):103–23.

[38] Viatte L, Gröne HJ, Hentze MW, Galy B. In vivo role(s) of the iron regulatory proteins (IRP) 1 and 2 in aseptic local inflammation. J Mol Med (Berl) 2009;87(9):913–21.

[39] Goforth JB, Anderson SA, Nizzi CP, Eisenstein RS. Multiple determinants within iron-responsive elements dictate iron regulatory protein binding and regulatory hierarchy. RNA 2010;16(1):154–69.

[40] Rouault TA. Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat Rev Neurosci 2013;14(8):551–64.

[41] Maher BH, Lea RA, Follitt J, et al. Association of a GRIA3 gene polymorphism with migraine in an Australian case-control cohort. Headache 2013;53(8):1245–9.

[42] de Vries B, Anttila V, Freilinger T, et al. International Headache Genetics Consortium. Systematic re-evaluation of genes from candidate gene association studies in migraine using a large genome-wide association data set. Cephalalgia 2016;36(7):604–14.

[43] Deplazes J, Schöbel K, Hochstrasser H, et al. Screening for mutations of the IRP2 gene in Parkinson’s disease patients with hyperechogenicity of the substantia nigra. J Neural Transm (Vienna) 2004;111(4):515–21.